Oral Answers to Questions Debate

Full Debate: Read Full Debate
Department: Cabinet Office

Oral Answers to Questions

Shaun Bailey Excerpts
Wednesday 10th June 2020

(4 years, 6 months ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Anne-Marie Trevelyan Portrait Anne-Marie Trevelyan
- Hansard - - - Excerpts

The UK Government condemn any action to restrict the freedom of expression of journalists, and have repeatedly raised the issue of internet restrictions and shutdowns at the highest level with the Myanmar Government, but, after going through due diligence, CDC invested in Frontiir to extend internet access to more people in Myanmar and to combat poverty. The company has followed the international Global Network Initiative standards by posting transparency statements so that users know whether the site has limitations upon it.

Shaun Bailey Portrait Shaun Bailey (West Bromwich West) (Con)
- Hansard - -

Wishing you a bostin’ birthday from the Black Country, Mr Speaker. I was recently lobbied by a year 12 student from Wednesbury called Queenie, who wanted to ensure that no one in the world cannot access a vaccine. So I wish to ask my right hon. Friend: in addition now to being the largest funder of Gavi, The Vaccine Alliance, what work is the UK doing and what message does she have for Queenie to ensure that she can carry on in her fight to make sure that everyone can access vaccines globally?

Anne-Marie Trevelyan Portrait Anne-Marie Trevelyan
- Hansard - - - Excerpts

Queenie is clearly a wise young person, and it is a really important question. The UK is at the forefront of efforts to drive global collaboration and resourcing, including through our engagement through the access to covid tools accelerator and through industry for the development of new vaccines at the speed and scale required to ensure access for all those who will need them. As well as contributing £1.65 billion to fund Gavi’s core programme we have committed £48 million to its newly launched covax advanced market commitment, aimed at incentivising manufacturers to produce sufficient quantities of a potential vaccine to ensure future access for low-income and middle-income countries.